Monthly Archives: May 2021

A local mum who was determined to heal her newborn babys eczema has debuted her vegan skincare range in H Beauty today (29/4).

Shalom Lloyd, a pharmacist from Milton Keynes, developed her own skincare range calledNaturally Tribal Skincare in 2014, after giving birth to twins.

Almost instantly her son, Joshua, suffered from extreme eczema and itchy irritation. Shalom couldnt bear the idea of smothering his sensitive newborn skin with chemicals and steroids. Instead, she looked to her African heritage for inspiration.

Recalling recipes containing all-natural ingredients, which have been used in Africa for generations, the busy mum started to experiment in her kitchen and soon Joshuas skin cleared and Shamon now boasts products that help with Psoriasis, Dermatitis and Rosacea too.

Shalom has put these ingredients intoNaturally Tribal SkincaresImperfectly Perfect range, which made its debut at H Beauty in the centre:mk upon the store's grand opening.

Although made here in the UK, Naturally Tribal Skincare, sources high-grade Shea Butter from Nigeria. The brand has also been a Vegan Trademark holder since 2017.

The Shea industry in Nigeria has over 16 million African women collecting and processing shea kernels as a main source of income and in 2020, Naturally Tribal built and opened the Essan factory which currently employs 20 local women.

Reacting to the announcement, founder Shalom Lloyd said: This wonderful milestone brings my proud dual British and African heritage to life. We know we have great products that work and we are built on incredibly strong values. We know that we are a company that is diverse. So, being part of the H beauty Milton Keynes Born & Bred line up is something to be extremely proud of.

Having the Vegan Trademark also makes a huge difference and lets our customers know that what theyre buying is completely natural and free from animal ingredients and testing.

Read the original:
Milton Keynes mum's natural skincare range that cured her son's eczema is being sold at H Beauty in Milton Keynes - MKFM

A systematic review and network meta-analysis of systemic atopic dermatitis therapies suggest upadacitinib, abrocitinib, and dupilumab are associated with the best efficacy outcomes among the robust drug class options.

The research, presented at theAmerican Academy of Dermatology (AAD) Virtual Meeting Experience this weekend, provides a unique comparison of systemic agents for key outcomes in moderate to severe atopic dermatitis treatment, including Eczema Area Severity Index (EASI) and Investigators Global Assessment (IGA) scores.

Led by Jonathan I. Silverberg, MD, PhD, MPH, of the George Washington University School of Medicine and Health Sciences, investigators conducted a systematic literature review and a network meta-analysis of randomized controlled trials observing systemic therapy in adults and adolescents with atopic dermatitis.

As they noted, head-to-head systemic therapy trials are lacking in atopic dermatitis. They hypothesized a meta-analysis could provide comparative context into the efficacy and safety of such agents and could even inform clinical decisions.

The Pfizer-sponsored assessment observed both monotherapy and combination systemic therapy in published research for atopic dermatitis. Silverberg and colleagues conducted analysis of randomized controlled trials including adult and adolescent patients through October 24, 2019.

Short-term efficacy, defined as 12-16 weeks of systemic therapy for EASI and IGA responses, as well as safety data were analyzed in fixed-effects and random-effects Bayesian network meta-analysis models.

The team found 19 published phase 2 or 3 randomized controlled trials involving abrocitinib, baricitinib, dupilumab, lebrikizumab, nemolizumab, tralokinumab, and upadacitinib.

In monotherapy use, once-daily 30 mg upadacitinib was associated with the numerically highest rate of treatment efficacy (51.6% achieving EASI 90), followed by once-daily 200 mg abrocitinib (39.2%), once-daily 15 mg upadacitinib (34.5%), biweekly 200 mg dupilumab (27.6%), and once-daily 100 mg abrocitinib (22.2%).

In combination therapy use, the abrocitinib regimen was associated with a 48.7% rate of EASI 90. Other efficacious combination systemic therapy regimens included dupilumab (41.7%) and once-daily 100 mg abrocitinib (37.9%).

Investigators observed consistent benefits in IGA and patient-reported outcomes with the systemic therapy regimens.

Treatment-emergent adverse events were more common in every active treatment regimen than in placebo, aside for biweekly 300 mg dupilumab (OR, 0.96; 95% CI, 0.45 2.18) and once-daily 100 mg abroctinib (OR, 0.95; 95% CI, 0.35 2.66), both used in combination therapy for atopic dermatitis.

The investigators concluded the assessment showed favor on efficacy and safety marks to both monotherapy and combination abrocitinib and dupilumab among other atopic dermatitis systemic therapies.

To conclude, abrocitinib, dupilumab, and upadacitinib were consistently the most effective systemic therapies in adults and adolescents with atopic dermatitis, Silverberg said. Abrocitinib and dupilumab combination therapy demonstrated the greatest efficacy, and there was no significant difference in treatment-emergent adverse events in these short-term randomized controlled trials, although there were some numerical increases observed.

The study, Comparative Efficacy and Safety of Systemic Therapies Used in Adult and Adolescent Moderate-to-Severe Atopic Dermatitis (AD): A Systematic Literature Review (SLR) and Network Meta-Analysis (NMA), was presented at AAD VMX.

See the rest here:
What Are The Best, Safest Systemic Therapies for Atopic Dermatitis? - MD Magazine

Atopic dermatitis and eczema, nail diseases, and hair loss are significantly associated with depression in children and adolescents, researchers reported in the Journal of Affective Disorders.

The retrospective case-control study enrolled children and adolescents diagnosed with depression for the first time in 185 pediatric practices in Germany from January 2017 to December 2019, and matched control participants without depression. Data were obtained from the Disease Analyzer database. The analysis included 9 skin conditionsatopic dermatitis and eczema, urticaria, nail disorders, hair loss, acne, rosacea, pigmentation disorders, epidermal thickening, and atrophic disorders of the skin.

A total of 7061 children and adolescents with depression and 7061 matched control participants without depression were included (mean [SD] age, 11.3 [3.8] years; 53.4% girls, for both groups). Among the participants with depression, approximately 4.7% had mild depression, 16.5% had moderate depression, 2.6% had severe depression, and the others (76.3%) had undefined depression.

Continue Reading

Regression analysis showed that atopic dermatitis and eczema (odds ratio [OR], 1.50; 95% CI, 1.37-1.64), nail disorders (OR, 1.84; 95% CI, 1.20-2.82), and hair loss (OR, 1.84; 95% CI, 1.30- 2.60) were significantly associated with depression.

Sex-stratified regression analysis demonstrated that atopic dermatitis and eczema (OR, 1.43; 95% CI, 1.26-1.61) and hair loss (OR, 2.04; 95% CI, 1.37-3.03) were significantly associated with depression among women patients, and atopic dermatitis and eczema were associated with depression (OR, 1.58; 95% CI, 1.39-1.80) in men patients. In addition, a strong nonsignificant association was observed for nail disorders (OR, 2.07; 95% CI, 1.07-4.01) and pigmentation disorders (OR, 1.93; 95% CI, 1.05-3.54) in women participants.

The study has several limitations, according to the investigators. Diagnoses of depression and other disorders were based on ICD-10 codes, and no information was available regarding the duration or intensity of the respective illness or location of the skin lesions. Data were also lacking for potential confounders such as socioeconomic status, social support, and psychosocial stressors.

One important factor that is common to all associated conditions is a possible impact on the external appearance of the patient, especially due to skin lesions affecting the face, head, or hands, the researchers commented. This physical change and environmental reactions to it can cause low self-esteem, feelings of embarrassment, and depression in young people, as they are in a critical phase of development during which they are likely to compare themselves to others.

Teichgrber F, Jacob L, Koyanagi A, Shin JI, Seiringer P, Kostev K. Association between skin disorders and depression in children and adolescents: a retrospective case-control study. J Affect Disord. 2021;282:939-944. doi:10.1016/j.jad.2021.01.002

The rest is here:
Skin Disorders Linked to Depression in Children and Adolescents - Dermatology Advisor

Findings from Facts and Factors reportAtopic Eczema Treatment Market By Type (Topical, Oral, and Injectable), By Application (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 2026states that the globalAtopic Eczema Treatment marketin 2019 was approximately USD 18,057.4 Million. The market is anticipated to grow at a CAGR of 10.36% and is anticipated to reach around USD 34,089.3 Million by 2026.

Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is more common in children and can become more serious as they get older. Atopic dermatitis is caused by a genetic mutation, environmental contamination, immune system dysfunction, and skin permeability issues. Dry skin, irritants, fatigue, allergies, infection, and heat/sweating are the primary causes of atopic dermatitis. Its important to remember that these just cause atopic dermatitis symptoms; they dont cause atopic dermatitis. Atopic dermatitis (AD) is a widespread chronic skin disorder that has been linked to other atopic diseases. Although there is growing evidence of a connection with non-atopic conditions, such as autoimmune disorders, data on many autoimmune diagnoses is restricted.

Dermatological disorders are exceedingly common in different forms all over the world. According to the World Health Organization, skin diseases affected over 900 million people in 2017. Atopic dermatitis is the most common of these diseases, affecting over 300 million people worldwide. Children make up about a quarter of the victims. The increased prevalence of this disease is projected to have a positive impact on the economy. In recent years, increased understanding of the diseases therapeutic options has aided the markets survival. Government initiatives to ensure quality and more affordable care, as well as the availability of favorable reimbursement plans, are expected to boost the sector. During the study era, developing country health growth and evolution would present new opportunities.

Request Download Link for PDF Sample Report With COVID-19 Impact Analysis Herehttps://www.fnfresearch.com/sample/atopic-eczema-treatment-market

The infected area produces white fluid, which necessitates treatment. Atopic dermis normally starts in childhood and gets worse as you get older. Atopic dermatitis is caused by a combination of genetics, environmental toxicity, immune system dysfunction, and skin permeability issues.

Based on type market is bifurcated into categories such as topical, oral, and injectable. A Topicalcategory is estimated to hold the largest market share of the atopic eczema treatment market. The cream-based solution for treatment is making the product easy for an application, which is expected to surge a market demand in forecast years. In addition to this, based on application, the market is bifurcated into categories such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Retail pharmacies are estimated to hold the largest market share of the atopic eczema market. However, online pharmacies are estimated to grow at a significant CAGR owing to the penetration of mobile phones and the emergence of numerous medicine delivery startups.

Because of new product releases, early treatment acceptance, and lifestyle improvements, North America was the largest market for the treatment of atopic dermatitis in 2019. North America emerged as the leading market for atopic dermatitis, owing to higher treatment knowledge among the target population, early acceptance of novel drugs, and better reimbursement policies, according to the regional study. Europe has the second-largest share of the market. The key driver of the demand in this area is large-scale R&D spending. The Asia-Pacific region is projected to rise the fastest between 2020 and 2026, owing to increasing demand. Due to increasing health expenditure and the availability of adequate care, the Asia-Pacific region is expected to rise the fastest between 2020 and 2026.

Inquire To Know Additional List of Market Players Included, Request Herehttps://www.fnfresearch.com/inquiry/atopic-eczema-treatment-market

Top Market Players

Some of the key players in the atopic eczema treatment market are Encore Dermatology Inc., AbbieVie Inc., LEO Pharma A/S, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline plc.,Sanofi S.A., Regeneron Pharmaceuticals Inc., LEO Pharma A/S, and Medimmune LLC. (AstraZeneca), among others. The aforementioned companies primary strategy for market growth is to invest in the research and production of new prescription products. Sanofi Genzyme, for example, makes the Biologics medication DUPIXNET , which treats skin lesions and relieves scratching.

According to the 2017 Global Burden of Disease research database, atopic eczema is the leading cause of skin-related impairment, affecting up to 24 percent of the global population, according to JAAD International. Up to 23% of nurses suffer from occupational dermatitis, with daily hand washing and the use of protective gloves being major risk factors. The COVID-19 pandemic has risen in cases of skin irritation and disease in health-care workers as a result of excessive use of personal protective equipment (PPE) and chronic stress, which exacerbates atopic eczema. Hand washing is a popular recommendation for preventing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is expected to affect more people than just health-care staff as dermatitis cases rise. As a result, the global COVID-19 pandemic is predicted to benefit the atopic eczema treatment industry.

This report segments the Atopic Eczema Treatment market as follows:

Global Atopic Eczema Treatment Market:By Type Based Segmentation Analysis:

Global Atopic Eczema Treatment Market: By Application Segmentation Analysis

Global Atopic Eczema Treatment Market: Regional Segmentation Analysis

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:Facts & FactorsA 2108, Sargam,Nanded City,Sinhagad Road,Pune 411041, IndiaUSA: +1 (347) 690-0211Email:sales@fnfresearch.comWeb:https://www.fnfresearch.com

Excerpt from:
Atopic Eczema Treatment Market projected to Reach USD 34089.3 Million by 2026 The Courier - The Courier

Accepting that having acne was my new normal, it opened up a portal in my life, says influencer Nazhaya Barce Barcelona. In the fall of her sophomore year of college, she returned to school with her face in an acne breakout that only worsened over time. I couldn't put my finger on the root of the issue for years," she recalls. "I blamed it on so many things: skin-care products, hair products, food, the water in my college town."

Unlike many of the other skin ailments featured in this piece, acne is something most people encounter (up to 85 percent of us, in fact). But, as Aguh explains, it can present differently on darker skin, and treatment may look different as well. While acne pimples look similar in all skin tones, Aguh explains, acne is more likely to leave behind spots of discoloration in more deeply pigmented skin tones, which feels like a problem caused by another problem. For this reason, when treating acne in brown skin, it is very important to use medications that will not only treat the active, inflamed acne pimples, but also are designed to treat the discoloration as well, says Diggs.

For Barcelona, a visit to the dermatologist meant she had medical intervention: "My first time going to the dermatologist, I was very excited to get a topical prescription that was medically engineered to clear my skin."

But a doctor's prescription can only do so much; treatment required work on her mental health too. Barcelona felt that acne had tainted her membership in the community of "beautiful people." With acne, Barcelona shares, "self-love and self-discovery presented itself to me in a way I would've never experienced if I had clear skin all my life." She explains, I had to navigate social interactions, romantic relationships, and self-reflection with a new face. Acne created a mental and spiritual wound that was very painful and uncomfortable to wear every day. It blinded me to who I really was.

Then, one day, Barcelona continues, "I decided to be brave. I was exhausted from trying to hide and feeling shame about how I looked. I told myself that I wasn't going to torture myself like this anymore. I wasn't sure if people really thought I looked as disgusting and scary as I thought I did, but I decided that day that even if they did, I didn't care anymore. I was beautiful before the acne, and I'll continue to be beautiful with it."

Read the original:
Black Women With Skin Conditions Share Their Paths to Diagnosis - Allure

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Four Indications in Clinical Development

JUPITER, FL / ACCESSWIRE / April 29, 2021 / Jupiter Wellness, Inc. (NASDAQ: JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced an update on its clinical pipeline of CBD-based therapeutic topical formulations including JW-100 for the treatment of eczema, JW-200 for skin cancer, JW-300 for burns, and JW-400 for herpes cold sores.

Commenced Patient Enrollment for Skin Cancer: Study Completion Expected Q4 2021

Jupiter's JW-200 is designed to provide action and relief in the treatment of Actinic Keratosis (AK), the most common precancer that forms on skin as a result of exposure to ultraviolet (UV) rays. The objective of this double blinded, placebo-controlled study is to evaluate the efficacy of JW-200 in both the treatment and prevention of disease, with a primary efficacy endpoint of the percentage of patients with complete clearance of AK lesions. An estimated 120 adults diagnosed with AK will be recruited, with an expected study completion date of Q4 2021.

The Skin Cancer Foundation estimates 58 million Americans have one or more AK lesions which appear as raised, scaly discolored patches on sun-exposed skin. Left untreated, approximately 20% of AK lesions progress to squamous cell carcinoma. The skin cancer treatment market was $8.19 billion 2019 and is estimated to reach $14.55 billion by 2027.

Patient Recruitment Started for First Degree Burns: Topline Data Expected Q4 2021

JW-300 is being evaluated in a clinical study for the treatment of first-degree burns resulting from sun exposure. The double blinded, placebo-controlled trial is recruiting an estimated 44 patients who have first degree burns induced by UVB irradiation. The primary endpoint is the reduction in erythema within 24 hours of treatment. The trial is expected to be completed in Q3 2021, with topline data expected Q4 2021.

Preparing for Upcoming IND Meeting with U.S. FDA for Eczema Phase I/II Study

Jupiter is preparing for a meeting in Q3 2021 with the U.S. Food and Drug Administration (FDA) regarding the Company's Investigational New Drug (IND) application that it expects to file. The Company will propose its clinical protocol for a Phase I/II study based on the efficacy and safety shown in the recently completed exploratory study of JW-100 for the treatment of atopic dermatitis (eczema). The study showed that JW-100 cleared or reduced eczema following two weeks of use in more than half of the subjects, achieving ISGA clear or almost clear (1 or 2) with at least a 2-grade improvement from baseline after treatment, versus 20% and 15% in the CBD-only and placebo arms.

The global eczema market is valued at $10 billion and is expected to grow at a CAGR of 13% through 2025. Ten percent of the U.S. population, or 31.6 million people, have eczema, and according to NationalEczema.org, 86% of people are not satisfied with their current treatment.

JW-400 for Treatment of Herpes Cold Sores Expected to Commence Recruitment Q4 2021

The double blind, placebo controlled study is now preparing for recruitment of 40 patients with recurrent herpes labialis infection (HSV) who had their initial infection more than one year prior. The primary endpoint is the duration of the herpes labialis episode. The herpes simplex virus treatment market was $4.8 billion in 2017. Nearly half of Americans age14-29 have HSV-1, known as the cold sore virus.

"With multiple study completion and topline data milestones upcoming in 2021 and early 2022, we are very pleased with the pace and scope of our clinical programs which address substantial market opportunity and clinical needs for more effective therapies," stated Brian John, CEO of Jupiter Wellness.

About Jupiter Wellness

Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products. The Company's clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun" sunscreen and other wellness brands sold through its robust distribution platform.

For additional information, please visit http://www.jupiterwellnessinc.com. The Company's public filings can be found at http://www.Sec.gov.

Safe Harbor Statement

To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company's industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor & Public Relations Contact InfoPhone: 561-244-7100Email: info@jupiterwellness.com

SOURCE: Jupiter Wellness, Inc.

View source version on accesswire.com: https://www.accesswire.com/643224/Jupiter-Wellness-Advances-Clinical-Pipeline-of-CBD-Based-Topical-Treatments

See the original post:
Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments - StreetInsider.com